The immune system's reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple ...

Our results provide mechanistic evidence that immune responses to EBV can directly damage the brain in MS,” said Olivia Thomas, PhD, assistant professor at the Department of Clinical Neuroscience at ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

The immune system's reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple sclerosis (MS). This is shown ...

The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.

The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a ​rare form of blood ...

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...

Silintan capsules, a dietary supplement marketed for joint and body aches, have been recalled due to the presence of ...

The FDA declined to approve EBVALLO (tabelecleucel), Atara’s treatment for Epstein-Barr virus positive post-transplant ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...